Switching From Zepbound to Wegovy: The Question Nobody Tells You to Ask

Last reviewed 13 August 2026 · Educational, not medical advice · Dose changes are a decision for your prescriber · No sponsorships, no affiliate links

There is no official conversion, and you should be suspicious of charts that claim one

Neither Eli Lilly nor Novo Nordisk publishes a cross-product dose conversion, and the FDA has never issued one. These drugs were approved as separate therapies, not as interchangeable products. Any "Zepbound to Wegovy conversion chart" you find online is a practice pattern someone wrote down, not a validated equivalence.

The pharmacology explains why one cannot exist. Tirzepatide activates two receptors and semaglutide activates one, so the dose-response curves are not parallel. Equivalence at one point on the ladder would not predict equivalence at another. There is no exchange rate between these molecules because they are not the same currency.

What prescribers actually do is restart the new drug low and titrate on response rather than trying to match your old dose. The usual sequencing is to take the first Wegovy dose about a week after the last Zepbound dose, keeping the weekly rhythm intact. Where on the Wegovy ladder to begin is a clinical judgement that depends on how long you were on tirzepatide, how well you tolerated it, and how much room your prescriber wants for side effects - which is exactly the conversation to have rather than a number to look up.

What to expect through the transition

The honest version, which is rarely stated: the switch has a cost, and the cost lands in the middle.

• Re-titration takes about four months. Wegovy climbs 0.25 to 0.5 to 1 to 1.7 to 2.4 mg with four weeks at each step. During that climb you are on less appetite suppression than you were used to.
• A plateau or modest regain in that window is normal, not a sign the new drug is failing. The drug has not had time to reach its working dose.
• Gastrointestinal side effects come back. Nausea and constipation cluster after dose increases, and you are about to do four of them. In SURMOUNT-5, GI events drove 5.6% of semaglutide patients off the drug entirely, twice the tirzepatide rate.
• Do not leave a long gap. If a coverage change forces the switch, the worst outcome is weeks with no drug at all while paperwork clears. Appetite returns fast.

Why people do this, and what to try first

Formulary changes. By far the most common reason. Plans move between Novo Nordisk and Lilly contracts, and patients move with them. Before switching, it is worth having your prescriber check whether an exception or appeal is possible, particularly if you have an indication Wegovy does not cover.

Cost. At self-pay rates in August 2026, Wegovy is $349 a month at every standard dose and Zepbound is $449 at maintenance - a $100 monthly saving. Worth knowing: Zepbound 12.5 mg and 15 mg vials revert to $849 and $1,049 if not refilled within 45 days, so an unnoticed lapse can make the gap look far larger than it is.

Sleep apnea is a reason not to. Zepbound holds the only drug approval of any class for moderate-to-severe obstructive sleep apnea in adults with obesity. If that is why you were prescribed it, a switch to Wegovy loses the indication entirely, and that is a strong argument for an appeal.

Heart or liver disease is a reason to. Wegovy is the only one of the two with placebo-controlled evidence that it prevents heart attacks and strokes - a 20% reduction across 17,604 patients in SELECT - and the only one approved for MASH with moderate-to-advanced fibrosis. If either applies to you, this switch is not a downgrade at all.

The dose question almost nobody raises

Standard practice is to titrate Wegovy to 2.4 mg and stop there, because that was the ceiling for years and it is the dose SELECT tested. But Wegovy HD at 7.2 mg was approved in March 2026, and in the STEP UP trial it produced 20.7% weight loss at 72 weeks against 17.5% for 2.4 mg. Over 90% of the 7.2 mg group lost at least 5% of body weight and a third lost 25% or more.

Cross-trial comparisons are not evidence, and STEP UP is not SURMOUNT-5. But if you are being moved off a drug that gave you 20.2% and onto one whose standard dose gave 13.7%, the existence of a higher dose that reached 20.7% in its own trial is directly relevant to your prescription and it is reasonable to ask about it.

Two caveats to carry into that conversation: the cardiovascular indication rests on 2.4 mg, not 7.2 mg, and higher doses of any GLP-1 drug mean more gastrointestinal side effects.

Get a baseline before you switch, not after

This is the single most useful thing on the page, and it has a deadline: the data you need is the data from before you stop. Once you are three weeks into re-titration and the scale has not moved, there is no way to reconstruct what your last month on Zepbound actually looked like, and no way to tell an expected plateau from a genuine failure. You will be making a decision about an expensive drug on the basis of a feeling.

So before the last Zepbound dose: log four weeks of weekly weights at a fixed time, your current dose, and your typical side-effect load. That is your control. Then log weekly through the sixteen weeks of climbing back up. When week six looks flat - and it probably will, because you are at a fraction of a working dose - you will be able to see that it is the expected shape of the curve rather than proof the new drug does not work for you. That is the week most people abandon the switch, and almost always too early.

Zenday App is our top-ranked GLP-1 companion at 4.55/5 and carries across the switch cleanly, which is the point - it holds doses, food, and side-effect days in one place from first injection through maintenance, so the pre-switch and post-switch periods sit in the same log rather than in two apps that cannot be compared. If the move was forced by a formulary decision you intend to appeal, Shotsy exports a dated clinician-ready PDF, and an appeal built on a documented response to the drug you were taken off is a far stronger document than one built on assertion. Both are scored in full in ourGLP-1 app ranking.

What the evidence does not show

• No trial has studied switching. Every practical statement on this page is drawn from pharmacology, from the head-to-head efficacy data, and from reported prescribing practice - not from a trial of people who switched.
• No validated dose equivalence exists, and the receptor difference makes one unlikely.
• Nothing quantifies regain during a transition. The expectation of a plateau is mechanistic reasoning, not a measured figure.
• Wegovy HD has no outcome trial and no head-to-head against tirzepatide.

Before you switch, ask your prescriber

• Is a formulary exception or appeal possible, particularly if I have a Zepbound-specific indication?
• Where on the Wegovy ladder should I start, given how long I have been on tirzepatide?
• How do we avoid a gap in supply while the change goes through?
• Is Wegovy HD 7.2 mg appropriate for me, or should we stop at 2.4 mg?
• What should I expect on the scale over the next four months, so I know what is normal?

Method and sources

Efficacy figures come from SURMOUNT-5, STEP UP, and SELECT as published. There is no trial of switching between these products; statements about clinical practice reflect reported prescribing patterns and are not a protocol. Prices are US manufacturer self-pay rates read on 13 August 2026. We take no money from either manufacturer and run no affiliate links. For the underlying comparison, see Wegovy vs Zepbound; for the reverse direction, see semaglutide to tirzepatide.